Difficulty: Medium
Average Score: 74%
Practice
A 47-year-old web designer has a 14-year history of ulcerative colitis. He recently moved to your area and presents to your office for continued management of his ulcerative colitis. He has been asymptomatic for the past two years and off all medications for one year with no rectal bleeding, diarrhea, abdominal pain, tenesmus, or fever. Before that he had very active colitis requiring steroids and immunosuppressants. He brings records from his previous physician that include his last three colonoscopy and pathology reports. The reports from 6 and 12 years ago documented active colitis with friable mucosa from the mid-transverse colon to the rectum, superficial ulcerations, crypt abscesses and crypt distortion, and acute and chronic inflammation. The most recent report, from almost three years ago, was fairly unremarkable endoscopically. Numerous random biopsies had been obtained. They showed mucosal changes on histology also consistent with a history of ulcerative colitis, but there was no evidence of active disease. What do you recommend?
Correct answer
D
Rationale
The correct answer is D: Do not start steroids; if stools are heme-occult positive, then refer for colonoscopy. In this scenario, the patient is asymptomatic for the past two years and off all medications for one year with no signs of active disease. Initiation of steroids is not indicated as the patient is currently in remission. However, given the history of ulcerative colitis and the risk of disease flare-ups, it is important to monitor for any signs of disease recurrence. Checking for heme-occult positive stools can be an early indicator of active disease. Referring for colonoscopy if stools are heme-occult positive allows for a more thorough evaluation of disease activity without unnecessary initiation of steroids. This approach balances the need for monitoring with avoiding unnecessary treatment. Other choices are incorrect as they either recommend starting steroids in a patient in remission (A, C) or do not incorporate monitoring for disease activity (B).